Tectonic Therapeutic, Inc. (NASDAQ:TECX - Get Free Report) insider Peter Mcnamara sold 536 shares of the business's stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $23.04, for a total value of $12,349.44. Following the sale, the insider owned 54,305 shares of the company's stock, valued at approximately $1,251,187.20. This represents a 0.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Peter Mcnamara also recently made the following trade(s):
- On Tuesday, August 25th, Peter Mcnamara sold 43 shares of Tectonic Therapeutic stock. The shares were sold at an average price of $36.52, for a total value of $1,570.36.
- On Wednesday, August 12th, Peter Mcnamara sold 43 shares of Tectonic Therapeutic stock. The stock was sold at an average price of $35.00, for a total value of $1,505.00.
Tectonic Therapeutic Stock Performance
NASDAQ:TECX traded down $0.13 during mid-day trading on Friday, hitting $22.54. 253,429 shares of the stock were exchanged, compared to its average volume of 264,623. The stock has a market capitalization of $440.66 million, a price-to-earnings ratio of -4.93 and a beta of 3.29. The firm's 50-day simple moving average is $30.36 and its 200 day simple moving average is $30.40. Tectonic Therapeutic, Inc. has a fifty-two week low of $14.60 and a fifty-two week high of $39.53.
Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.18) EPS for the quarter, beating analysts' consensus estimates of ($1.35) by $0.17. On average, analysts predict that Tectonic Therapeutic, Inc. will post -5.27 EPS for the current fiscal year.
Institutional Trading of Tectonic Therapeutic
Several large investors have recently made changes to their positions in TECX. BlackRock Inc. acquired a new position in shares of Tectonic Therapeutic during the 2nd quarter worth $29,652,000. Baker BROS. Advisors LP lifted its position in shares of Tectonic Therapeutic by 803.4% during the 4th quarter. Baker BROS. Advisors LP now owns 903,400 shares of the company's stock worth $18,845,000 after buying an additional 803,400 shares during the last quarter. First Light Asset Management LLC acquired a new stake in Tectonic Therapeutic in the first quarter valued at about $20,022,000. 5AM Venture Management LLC acquired a new stake in Tectonic Therapeutic in the second quarter valued at about $20,853,938. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Tectonic Therapeutic in the second quarter valued at about $2,232,000. Institutional investors and hedge funds own 62.63% of the company's stock.
Analysts Set New Price Targets
A number of research firms recently commented on TECX. Oppenheimer reaffirmed an "outperform" rating and set a $80.00 price target on shares of Tectonic Therapeutic in a research report on Wednesday. Wells Fargo & Company cut their price objective on shares of Tectonic Therapeutic from $101.00 to $93.00 and set an "overweight" rating for the company in a report on Friday, August 7th. TD Cowen restated a "buy" rating on shares of Tectonic Therapeutic in a research report on Wednesday. Wall Street Zen cut shares of Tectonic Therapeutic from a "sell" rating to a "strong sell" rating in a report on Saturday, September 19th. Finally, Zacks Research upgraded shares of Tectonic Therapeutic from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 18th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $77.80.
Read Our Latest Analysis on TECX
Tectonic Therapeutic Company Profile
(
Get Free Report)
Tectonic Therapeutic, Inc is a clinical-stage biotechnology company focused on developing biologic medicines that target G protein-coupled receptors (GPCRs). These receptors play important roles in many physiological processes but have historically been difficult to address with conventional antibody-based therapies.
The company uses its proprietary GEODe platform to discover and develop antibodies and other biologics designed to modulate GPCR activity. Tectonic's pipeline includes TX45, an investigational therapeutic intended to activate the relaxin receptor RXFP1.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tectonic Therapeutic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tectonic Therapeutic wasn't on the list.
While Tectonic Therapeutic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
